ArticleNPJ science of food2025
Astragali Radix-Carthami Flos alleviate brain-heart injury after cerebral ischemia/reperfusion via regulating TSPO signaling.
Article in NPJ science of food, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Ischemic stroke is often accompanied by secondary cardiac dysfunction, yet its underlying pathogenesis remains under investigation. Astragali Radix-Carthami Flos (ARCF) is a drug pair with medicine food homology, commonly used for cerebrovascular and cardiovascular diseases. This study found that in the middle cerebral artery occlusion/reperfusion rat model, ARCF management mitigated CI/R-induced brain-heart injury, as evidenced by improved neurological function, reduced cerebral and cardiac damage, restored serum biomarker levels, and enhanced overall cardiac function. Transcriptomic analysis, combined with network pharmacology and molecular docking, identified oxidative phosphorylation process and reactive oxygen species (ROS) production as key pathogenic mechanisms, with TSPO as a central target. Mechanistic studies revealed that the ARCF maintained mitochondrial homeostasis by inhibiting the TSPO/VDAC1/MCU pathway in the brain and the TSPO-VDAC1 axis in the heart. These findings highlight the potential of ARCF as a functional food-derived intervention for mitigating stroke-induced brain-heart injury, offering new insight into the food-based management of neurocardiac complications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.